Will Personalized Companion Diagnostics become the norm for diagnostics?
Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.
Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities. And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.
4.1 Recent Developments - Importance and How to Use This Section
4.1.1 Importance of These Developments
4.1.2 How to Use This Section
Genetron Health Targeting Early Cancer Detection
Pan-European Initiative to Build Tools for Sharing Genomic Data
UK Government Unveils New Genomic Healthcare Strategy
Foundation Medicine Liquid Biopsy Gets FDA Approval
American Heart Association Develops Genetic Testing Guidelines
Yourgene Health Gets CE Mark for Iona NIPT Test
NorthShore Looks to Expand Genomics Integration Into Primary Care
Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients
FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
BillionToOne Closes $15M Series A Follow-on Round
World Whole Genome and Exome Sequencing Markets, 2021-2025: COVID-19 Drives Overnight Global Growth in Pathogen Sequencing - A New Industry Emerges.
December 16, 2020 10:43 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
The COVID Pandemic has created a surge in Whole Genome Sequencing of Pathogens but cancer-related activity has suffered. Find out all about it in the comprehensive report of Whole Genome Sequencing. The complete genome of the COVID virus is included as an example of the work being done.
Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What s holding the industry back? Where are the over 800 locations that have high throughput devices?
World Human Gene Sequencing Markets, Strategies & Trends Report 2021-2025: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities
December 15, 2020 04:53 ET | Source: Research and Markets Research and Markets Dublin, IRELAND
ResearchAndMarkets.com s offering.
Will all newborns receive genetic testing at birth? Is COVID-19 holding the industry back? Where are the over 800 locations that have high throughput sequencing devices?
The plummeting costs for Genome Sequencing is creating a gold rush. New consumers, new technologies, new market niches. It is reminiscent of the birth of the internet industry; a wide range of well funded players are racing for market share on a global stage. This report forecasts the market size out to 2025. The report includes detailed breakouts for 14 countries and 5 regions.